Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Khiron Life Sciences Corp KHRNF


Primary Symbol: V.KHRN.H Alternate Symbol(s):  V.KHRN.W.H | KHRWF

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.


TSXV:KHRN.H - Post by User

Comment by Benedictuson Oct 28, 2020 10:17pm
142 Views
Post# 31800902

RE:Happy to average down at these prices!!

RE:Happy to average down at these prices!!

Have you done the math on script build in Columbia? 5000 or 10000 are a nice beginning but in a country with an annual per capita income of sub $7000 and expected revenue of around $350 or less for annual sales to loyal clients/patients, these early numbers just aren't going to move the market imo. If Columbia announces insurance coverage for medical cannabis or Mexico legalizes - those announcements will potentially move the stock.

The UK revenues from project 2021, which will potentially have 12,000 enrollees on the registry by eoy and hopefully meaningful sales beginning in Germany in Q4 - these are the markets with much higher per capita income medical  patients with insurance support.  All imo

<< Previous
Bullboard Posts
Next >>